{"id":53015,"date":"2018-09-27T01:00:00","date_gmt":"2018-09-30T01:40:06","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/09\/30\/%e9%82%a3%e4%ba%9b%e5%b9%b4%ef%bc%8c%e6%88%91%e4%bb%ac%e8%bf%bd%e8%bf%87%e7%9a%84%e6%98%8e%e6%98%9f%e8%8d%af%e4%b9%8b%e7%9b%90%e9%85%b8%e5%8e%84%e6%b4%9b%e6%9b%bf%e5%b0%bc\/"},"modified":"2018-09-30T09:40:09","modified_gmt":"2018-09-30T01:40:09","slug":"%e9%82%a3%e4%ba%9b%e5%b9%b4%ef%bc%8c%e6%88%91%e4%bb%ac%e8%bf%bd%e8%bf%87%e7%9a%84%e6%98%8e%e6%98%9f%e8%8d%af%e4%b9%8b%e7%9b%90%e9%85%b8%e5%8e%84%e6%b4%9b%e6%9b%bf%e5%b0%bc","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/53015\/","title":{"rendered":"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\u662f\u5168\u7403\u9996\u4e2a\u4f5c\u7528\u4e8e\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08EGFR\uff09\u916a\u6c28\u9178\u6fc0\u9176\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5242\uff0c\u4e5f\u662f\u9996\u4e2a\u7528\u4e8e\u80ba\u764c\u9776\u5411\u6cbb\u7597\u7684\u5c0f\u5206\u5b50\u836f\u7269\u3002\u8be5\u836f\u56e0\u4e3a\u9002\u5e94\u8bc1\u4eba\u7fa4\u5e9e\u5927\u3001\u56fd\u5916\u5e02\u573a\u8868\u73b0\u826f\u597d\u53ca\u65f6\u4e13\u5229\u5931\u6548\u65e5\u671f\u76f8\u5bf9\u8f83\u65e9\uff0c\u800c\u4e00\u5ea6\u662f\u56fd\u5185\u4eff\u5236\u836f\u4f01\u4e1a\u201c\u8ffd\u6367\u201d\u7684\u660e\u661f\u836f\u4e4b\u4e00\u3002<\/span><\/span><\/span>
<\/p>\n

<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n

 \u5168\u65873546\u5b57\uff0c\u7528\u65f67\u5206\u949f<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u4f5c\u8005\uff1a\u5411\u98de<\/span><\/p>\n

\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\uff08\u4e0b\u6587\u7b80\u79f0\u201c\u5384\u6d1b\u66ff\u5c3c\u201d\uff09\u662f\u5168\u7403\u9996\u4e2a\u4f5c\u7528\u4e8e\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08EGFR\uff09\u916a\u6c28\u9178\u6fc0\u9176\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5242\uff0c\u4e5f\u662f\u9996\u4e2a\u7528\u4e8e\u80ba\u764c\u9776\u5411\u6cbb\u7597\u7684\u5c0f\u5206\u5b50\u836f\u7269\u3002\u8be5\u836f\u56e0\u4e3a\u9002\u5e94\u8bc1\u4eba\u7fa4\u5e9e\u5927\u3001\u56fd\u5916\u5e02\u573a\u8868\u73b0\u826f\u597d\u53ca\u65f6\u4e13\u5229\u5931\u6548\u65e5\u671f\u76f8\u5bf9\u8f83\u65e9\uff0c\u800c\u4e00\u5ea6\u662f\u56fd\u5185\u4eff\u5236\u836f\u4f01\u4e1a\u201c\u8ffd\u6367\u201d\u7684\u660e\u661f\u836f\u4e4b\u4e00\u3002\u8fd1\u65e5\uff0c\u77e5\u540d\u533b\u5b66\u6742\u5fd7\u300a\u67f3\u53f6\u5200\u300b\uff08Lancet<\/em>\uff09\u7684\u5b50\u520a\u520a\u767b\u4e86\u6211\u56fd\u56fd\u5bb6\u764c\u75c7\u4e34\u5e8a\u7814\u7a76\u4e2d\u5fc3\u7684\u7814\u7a76\u4eba\u5458\u8fdb\u884c\u7684\u4e00\u9879\u5384\u6d1b\u66ff\u5c3c\u2161\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\uff0c\u4ece\u800c\u518d\u6b21\u5f15\u8d77\u4e86\u7b14\u8005\u5bf9\u5384\u6d1b\u66ff\u5c3c\u7684\u5173\u6ce8\u3002\u672c\u6587\u5373\u4ee5\u6587\u732e\u68c0\u7d22\u4e3a\u57fa\u7840\uff0c\u5e76\u7ed3\u5408\u4e2d\u56fd\u533b\u836f\u5de5\u4e1a\u4fe1\u606f\u4e2d\u5fc3PDB\u836f\u7269\u7efc\u5408\u6570\u636e\u5e93\u5bf9\u5384\u6d1b\u66ff\u5c3c\u7684\u6700\u65b0\u52a8\u6001\u8fdb\u884c\u4e86\u6574\u7406\u603b\u7ed3\u3002<\/span><\/p>\n

\n
\n

1<\/span>\u5384\u6d1b\u66ff\u5c3c\u6700\u65b0\u4e34\u5e8a\u7814\u7a76\u52a8\u6001<\/strong><\/p>\n<\/section>\n<\/section>\n

1\uff0cMaurel J et al. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Cancer Chemother Pharmacol. 2018 Sep 17. doi: 10.1007\/s00280-018-3682-9. [Epub ahead of print]<\/span><\/p>\n

    \n
  • \n

    \u8bd5\u9a8c\u76ee\u7684\uff1a\u521d\u6b65\u8bc4\u4ef7\u5409\u897f\u4ed6\u6ee8\u4e0e\u5384\u6d1b\u66ff\u5c3c\u65b0\u8f85\u52a9\u6cbb\u7597\u5bf9\u80bf\u7624\u53ef\u5207\u9664\u7684\u80f0\u817a\u5bfc\u7ba1\u817a\u764c\u60a3\u8005\u7684\u6709\u6548\u6027\u4e0e\u5b89\u5168\u6027\u3002<\/span><\/p>\n<\/li>\n

  • \n

    \u4e3b\u529e\u65b9\uff1a\u5df4\u585e\u7f57\u90a3\u5927\u5b66<\/span><\/p>\n<\/li>\n

  • \n

    \u8bd5\u9a8c\u5206\u671f\uff1a\u2161\u671f<\/span><\/p>\n<\/li>\n

  • \n

    \u53d7\u8bd5\u8005\u57fa\u672c\u7279\u5f81\uff1a\u80bf\u7624\u53ef\u5207\u9664\u7684\u80f0\u817a\u5bfc\u7ba1\u817a\u764c\u60a3\u8005<\/span><\/p>\n<\/li>\n

  • \n

    \u5165\u7ec4\u53d7\u8bd5\u8005\u4eba\u6570\uff1a25\u4eba<\/span><\/p>\n<\/li>\n

  • \n

    \u5e72\u9884\u65b9\u6cd5\uff1a\u65b0\u8f85\u52a9\u6cbb\u7597\u3002\u5177\u4f53\u7684\uff0c\u53d7\u8bd5\u8005\u63a5\u53d7\u4e09\u4e2a\u5468\u671f\u7684\u5409\u897f\u4ed6\u6ee8\uff081000 mg\/m2<\/sup>\/week\uff09\u8054\u5408\u5384\u6d1b\u66ff\u5c3c\uff08100mg\/d\uff09\u6cbb\u7597\uff0c\u91cd\u65b0\u5206\u7ea7\u540e\uff0c\u75c5\u60c5\u672a\u8fdb\u5c55\u7684\u53d7\u8bd5\u8005\u5219\u518d\u7528\u5409\u897f\u4ed6\u6ee8\uff08300 mg\/m2\/week\uff09\u3001\u5384\u6d1b\u66ff\u5c3c\uff08100mg\/d\uff09\u4e0e\u5316\u7597\uff0845 Gy\uff09\u6cbb\u75975\u5468\u3002\u91c7\u7528\u80bf\u7624\u9000\u5316\u7a0b\u5ea6\uff08TRG\uff09\u4e0e\u5207\u9664\u8fb9\u7f18\u72b6\u6001\u5bf9\u6709\u6548\u6027\u8fdb\u884c\u8bc4\u4ef7\uff0c\u53e6\u6839\u636e\u5355\u81c2Simon\u8bbe\u8ba1\uff0c\u82e5\u5b8c\u5168\u5207\u9664\u7387\uff08R0\uff09<40%\u5219\u8ba4\u4e3a\u5176\u65e0\u6548\uff0c\u800c\u82e5R0>70%\uff0c\u5219\u8ba4\u4e3a\u6709\u6548\u3002<\/span><\/p>\n<\/li>\n

  • \n

    \u4e3b\u8981\u7ed3\u679c\uff1a\u65b0\u8f85\u52a9\u6cbb\u7597\u7684\u4e0d\u826f\u53cd\u5e94\u4e3b\u8981\u7684\u8f7b\u5ea6\u7684\u6d88\u5316\u9053\u75c5\u75c7\u3002\u80bf\u7624\u5207\u9664\u7387\u4e3a76%\uff0c\u5728\u80bf\u7624\u5207\u9664\u7684\u53d7\u8bd5\u8005\u4e2d\uff0cR0\u5207\u9664\u7387\u4e3a63.1%\u3002\u603b\u751f\u5b58\u671f\u4e0e\u65e0\u75be\u75c5\u751f\u5b58\u671f\u7684\u4e2d\u4f4d\u503c\u5206\u522b\u662f23.8\uff0895% CI:11.4~36.2\uff09\u4e0e12.8\uff0895% CI:8.6~17.1\uff09\u4e2a\u6708\u3002R0\u5207\u9664\u7684\u53d7\u8bd5\u8005\u7684\u603b\u751f\u5b58\u671f\u4e2d\u4f4d\u503c\u4f18\u4e8eR1\u5207\u9664\u6216\u672a\u5207\u9664\u7684\u53d7\u8bd5\u8005\uff0865.5 vs 15.5\u6708\uff0cP=0.01\uff09\u3002\u80bf\u7624\u5207\u9664\u7684\u53d7\u8bd5\u8005\u4e2dN0\u7387\u4e3a63.1%\uff0c\u800c\u4e14\u5176\u603b\u751f\u5b58\u671f\u7684\u4e2d\u4f4d\u503c\u4e5f\u663e\u8457\u4f18\u4e8e\u672a\u5207\u9664\u7684\u53d7\u8bd5\u8005\uff0865.5 vs 15.2\u6708\uff0cP=0.009\uff09\u3002<\/span><\/p>\n<\/li>\n<\/ul>\n

    2\uff0cGettinger S. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018 Sep;13(9):1363-1372. Doi: 10.1016\/j.jtho.2018.05.015. Epub 2018 May 23.<\/span><\/p>\n

      \n
    • \n

      \u8bd5\u9a8c\u76ee\u7684\uff1a\u521d\u6b65\u8bc4\u4ef7\u90a3\u6b66\u5355\u6297\u8054\u5408\u5384\u6d1b\u66ff\u5c3c\u5bf9EGFR-\u7a81\u53d8\u6027\u665a\u671fNSCLC\u60a3\u8005\u7684\u5b89\u5168\u6027\u3002<\/span><\/p>\n<\/li>\n

    • \n

      \u4e3b\u529e\u65b9\uff1a\u8036\u9c81\u5927\u5b66\u764c\u75c7\u7814\u7a76\u4e2d\u5fc3\u3002<\/span><\/p>\n<\/li>\n

    • \n

      \u8bd5\u9a8c\u5206\u671f\uff1a\u2160\u671f<\/span><\/p>\n<\/li>\n

    • \n

      \u53d7\u8bd5\u8005\u57fa\u672c\u7279\u5f81\uff1a\u5148\u524d\u672a\u63a5\u53d7\u8fc7EGFR\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u6cbb\u7597\u6216\u867d\u7136\u63a5\u53d7\u8fc7TKI\u6cbb\u7597\u4f46\u672a\u63a5\u53d7\u8fc7\u5316\u7597\u7684\u665a\u671fEGFR\u7a81\u53d8\u6027NSCLC\u60a3\u8005\u3002<\/span><\/p>\n<\/li>\n

    • \n

      \u5165\u7ec4\u53d7\u8bd5\u8005\u4eba\u6570\uff1a21\uff08\u5305\u62ec20\u540d\u5148\u524d\u63a5\u53d7\u8fc7TKI\u6cbb\u7597\u7684\u60a3\u8005\u4e0e1\u540d\u672a\u63a5\u53d7\u8fc7TKI\u6cbb\u7597\u7684\u60a3\u8005\uff09<\/span><\/p>\n<\/li>\n

    • \n

      \u5e72\u9884\u65b9\u6cd5\uff1a\u53d7\u8bd5\u8005\u7528\u90a3\u6b66\u5355\u62973mg\/kg\u6cbb\u7597\uff0c\u6bcf2\u54681\u6b21\uff0c\u540c\u65f6\u7ed9\u4e88\u5384\u6d1b\u66ff\u5c3c150mg\/d\u6cbb\u7597\u76f4\u81f3\u75c5\u60c5\u51fa\u73b0\u8fdb\u5c55\u6216\u51fa\u73b0\u4e0d\u53ef\u63a5\u53d7\u7684\u6bd2\u6027\u53cd\u5e94\u3002\u4e3b\u8981\u7684\u7ed3\u5c40\u6307\u6807\u662f\u5b89\u5168\u6027\u4e0e\u8010\u53d7\u6027\u3002<\/span><\/p>\n<\/li>\n

    • \n

      \u4e3b\u8981\u7ed3\u679c\uff1a5\u540d\u53d7\u8bd5\u8005\u51fa\u73b0\u6cbb\u7597\u76f8\u5173\u7684\u6bd2\u6027\u53cd\u5e94\uff0c\u5305\u62ec2\u4f8b\u809d\u9176\u6c34\u5e73\u4e0a\u5347\uff0c2\u4f8b\u8179\u6cfb\u4e0e1\u4f8b\u4f53\u91cd\u51cf\u8f7b\uff0c\u6240\u6709\u53d7\u8bd5\u8005\u5747\u672a\u51fa\u73b04\u7ea7\u6216\u9ad8\u4e8e4\u7ea7\u7684\u6bd2\u6027\u53cd\u5e94\u3002\u63a5\u53d7\u8fc7TKI\u6cbb\u7597\u7684\u4eba\u7fa4\u4e2d\uff0c\u5ba2\u89c2\u7f13\u89e3\u7387\u4e3a15%\uff083\/20\uff0c\u5305\u62ec1\u4f8b\u5b8c\u5168\u7f13\u89e3\uff09\uff0c24\u5468\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\u4e3a48%\u3002\u75c5\u60c5\u7684\u7f13\u89e3\u6548\u679c\u53ef\u6301\u7eed13.8\u300117.6\u4e2a38.2\u4e2a\u6708\u30021\/4\u53d7\u8bd5\u8005\u51fa\u73b0\u975e\u5e38\u89c4\u6027\u514d\u75ab\u76f8\u5173\u6027\u7f13\u89e3\uff0c\u800c\u4e14\u5176\u6548\u679c\u53ef\u6301\u7eed12.5\u4e2a\u6708\u3002<\/span><\/p>\n<\/li>\n

    • \n

      \u4e3b\u8981\u7ed3\u8bba\uff1a\u90a3\u6b66\u5355\u6297\u8054\u5408\u5384\u6d1b\u66ff\u5c3c\u5728\u5148\u524d\u63a5\u53d7\u8fc7TKI\u6cbb\u7597\u7684EGFR\u7a81\u53d8\u6027NSCLC\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u7279\u5f81\uff0c\u800c\u4e14\u5176\u7f13\u89e3\u6548\u679c\u6301\u4e45\u3002<\/span><\/p>\n<\/li>\n<\/ul>\n

      3\uff0cGaron EB. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016\/j.lungcan.2018.06.013. Epub 2018 Jun 22.<\/span><\/p>\n

        \n
      • \n

        \u8bd5\u9a8c\u76ee\u7684\uff1a\u8bc4\u4ef7\u6c1f\u7ef4\u53f8\u7fa4\u8054\u5408\u5384\u6d1b\u66ff\u5c3c\u5bf9\u665a\u671fNSCLC\u60a3\u8005\u7684\u6297\u80bf\u7624\u4f5c\u7528<\/span><\/p>\n<\/li>\n

      • \n

        \u4e3b\u529e\u65b9\uff1a\u7f8e\u56fd\u6234\u536b.\u683c\u82ac\u533b\u5b66\u5b66\u9662<\/span><\/p>\n<\/li>\n

      • \n

        \u8bd5\u9a8c\u5206\u671f\uff1a\u2161\u671f<\/span><\/p>\n<\/li>\n

      • \n

        \u53d7\u8bd5\u8005\u57fa\u672c\u7279\u5f81\uff1a\u5148\u524d\u63a5\u53d7\u8fc7\u5316\u7597\uff08\u4e3b\u52a8\u62d2\u7edd\u8005\u9664\u5916\uff09\u4f46\u672a\u63a5\u53d7\u8fc7EGFR\u7597\u6cd5\u7684\u665a\u671f\u6216\u8f6c\u79fb\u6027NSCLC\u60a3\u8005\u3002<\/span><\/p>\n<\/li>\n

      • \n

        \u5165\u7ec4\u53d7\u8bd5\u8005\u4eba\u6570\uff1a106\u4eba\u3002<\/span><\/p>\n<\/li>\n

      • \n

        \u5e72\u9884\u65b9\u6cd5\uff1a\u53d7\u8bd5\u8005\u63092:1\u7684\u6bd4\u4f8b\u968f\u673a\u5206\u5165\u8054\u5408\u7528\u836f\u7ec4\u4e0e\u5384\u6d1b\u66ff\u5c3c\u5355\u72ec\u7528\u836f\u7ec4\uff0c\u5176\u4e2d\u8054\u5408\u7528\u836f\u7ec4\u5728\u6bcf\u5929\u7ed9\u4e88\u5384\u6d1b\u66ff\u5c3c150mg\u7684\u540c\u65f6\u4e8e\u7b2c1\u300115\u300129\u5929\u4ee5\u53ca\u6b64\u540e\u6bcf28\u5929\u4e00\u6b21\u7ed9\u4e88\u6c1f\u7ef4\u53f8\u7fa4500mg im\u6cbb\u7597\u3002\u4e3b\u8981\u7684\u7ed3\u5c40\u6307\u6807\u662f\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\uff0c\u6b21\u8981\u7ed3\u5c40\u6307\u6807\u5305\u62ec\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u4e0e\u603b\u751f\u5b58\u671f\uff08OS\uff09\u3002<\/span><\/p>\n<\/li>\n

      • \n

        \u4e3b\u8981\u7ed3\u679c\uff1a\u8054\u5408\u7528\u836f\u7ec4\u4e0e\u5355\u72ec\u7528\u836f\u7ec4\u7684ORR\u5206\u522b\u4e3a16.4%\uff0811\/67\uff09\u4e0e12.1%\uff084\/33\uff09\uff0c\u4e24\u7ec4\u76f8\u6bd4\u65e0\u7edf\u8ba1\u5b66\u663e\u8457\u6027\u5dee\u5f02\uff08P=0.77\uff09\u3002\u4e24\u7ec4\u7684PFS\u4e2d\u4f4d\u503c\u5206\u522b\u4e3a3.5\u6708\u4e0e1.9\u6708\uff08HR\u202f=\u202f0.86, 95% CI\uff1a0.52-1.43, p\u202f=\u202f0.29\uff09\uff0c\u800c\u4e24\u7ec4\u7684OS\u4e2d\u4f4d\u503c\u5206\u522b\u4e3a9.5\u4e2a\u6708\u4e0e5.8\u4e2a\u6708\uff08HR\u202f=\u202f0.92, 95% CI \uff1a0.57-1.48\uff0cp\u202f=\u202f0.74\uff09\uff0c\u8054\u5408\u7528\u836f\u7ec4\u5728\u6570\u5b57\u4e0a\u4f18\u4e8e\u5355\u72ec\u7528\u836f\u7ec4\u3002\u6309\u8ba1\u5212\u8fdb\u884c\u7684\u4e00\u9879\u4e9a\u7ec4\u5206\u6790\u7ed3\u679c\u663e\u793a\uff0cEGFR\u91ce\u751f\u578b\u53d7\u8bd5\u8005\u4e2d\uff0c\u8054\u5408\u7528\u836f\u7ec4\u4e0e\u5355\u72ec\u7528\u836f\u7ec4\u7684PFS\u4e2d\u4f4d\u503c\u5206\u522b\u4e3a3.5\u4e2a\u6708\u4e0e1.7\u4e2a\u6708\uff08HR\u202f=\u202f0.35, 95% CI\uff1a0.14-0.86\uff0cp\u202f=\u202f0.02\uff09\uff0c\u800c\u4e24\u7ec4\u7684OS\u4e2d\u4f4d\u503c\u5206\u522b\u4e3a6.2\u4e2a\u6708\u4e0e5.2\u4e2a\u6708\uff08HR\u202f=\u202f0.72, 95% CI\uff1a0.35-1.48\uff0c p\u202f=\u202f0.37\uff09\u3002\u53e6\u5916\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cEGFR\u91ce\u751f\u578b\u53d7\u8bd5\u8005\u5448\u6fc0\u7d20\u53d7\u4f53\u9633\u6027\u7684\u6982\u7387\u663e\u8457\u9ad8\u4e8eEGFR\u7a81\u53d8\u7684\u53d7\u8bd5\u8005\uff0850% vs 9.1%\uff0cP=0.03\uff09\u3002\u8054\u5408\u7528\u836f\u4e0e\u5355\u72ec\u7528\u836f\u5747\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u7279\u5f81\uff0c\u4e3b\u8981\u7684\u4e0d\u826f\u53cd\u5e94\u4e3a1~2\u7ea7\u7684\u76ae\u80a4\u4e0e\u6d88\u5316\u9053\u4e0d\u826f\u53cd\u5e94\u3002<\/span><\/p>\n<\/li>\n

      • \n

        \u4e3b\u8981\u7ed3\u8bba\uff1a\u6c1f\u7ef4\u53f8\u7fa4\u8054\u5408\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u7279\u5f81\uff0c\u800c\u4e14\u5bf9EGFR\u91ce\u751f\u578b\u53d7\u8bd5\u8005\u7684\u6709\u6548\u6027\u4f18\u4e8e\u5384\u6d1b\u66ff\u5c3c\u5355\u72ec\u7528\u836f\u3002<\/span><\/p>\n<\/li>\n<\/ul>\n

        4\uff0cXiong L. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Oncologist. 2018 Aug 29. pii: theoncologist.2018-0120. doi: 10.1634\/theoncologist.2018-0120. [Epub ahead of print]<\/span><\/p>\n

          \n
        • \n

          \u8bd5\u9a8c\u76ee\u7684\uff1a\u8bc4\u4ef7\u5384\u6d1b\u66ff\u5c3c\u65b0\u8f85\u52a9\u6cbb\u7597\u662f\u5426\u80fd\u6539\u5584\u2162A~N2\u7ea7EGFR\u7a81\u53d8\u9633\u6027\u7684NSCLC\u60a3\u8005\u7684\u53ef\u624b\u672f\u6027\u4e0e\u751f\u5b58\u6548\u679c\u3002<\/span><\/p>\n<\/li>\n

        • \n

          \u4e3b\u529e\u65b9\uff1a\u4e0a\u6d77\u4ea4\u901a\u5927\u5b66\u9644\u5c5e\u80f8\u79d1\u533b\u9662\u3002<\/span><\/p>\n<\/li>\n

        • \n

          \u8bd5\u9a8c\u5206\u671f\uff1a\u2161\u671f<\/span><\/p>\n<\/li>\n

        • \n

          \u53d7\u8bd5\u8005\u57fa\u672c\u7279\u5f81\uff1a\u80bf\u7624\u53ef\u5207\u9664\u7684\u2162A~N2\u7ea7EGFR-\u7a81\u53d8\u9633\u6027NSCLC\u60a3\u8005\u3002<\/span><\/p>\n<\/li>\n

        • \n

          \u5165\u7ec4\u53d7\u8bd5\u8005\u4eba\u6570\uff1a19\u4eba\uff08\u7eb3\u5165\u6700\u7ec8\u5206\u6790\uff09<\/span><\/p>\n<\/li>\n

        • \n

          \u5e72\u9884\u65b9\u6cd5\uff1a\u65b0\u8f85\u52a9\u671f\u5185\u7528\u5384\u6d1b\u66ff\u5c3c150mg\/d\u8fde\u7eed\u6cbb\u759756\u5929\uff0c\u4e3b\u8981\u7684\u7ed3\u5c40\u6307\u6807\u662f\u5b8c\u5168\u5207\u9664\u7387\u3002<\/span><\/p>\n<\/li>\n

        • \n

          \u4e3b\u8981\u7ed3\u679c\uff1a\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u540e\uff0c14\u540d\u53d7\u8bd5\u8005\u63a5\u53d7\u4e86\u624b\u672f\u5207\u9664\u80bf\u7624\uff0c\u5176\u5b8c\u5168\u5207\u9664\u7387\u4e3a68.4%\uff0813\/19\uff09\uff0c\u800c\u75c5\u7406\u5206\u7ea7\u964d\u4f4e\u7387\u4e3a21.1%\uff0817\/19\uff09\u3002ORR\u4e3a42.1%\uff0c\u53e6\u670989.5%\uff0817\/19\uff09\u7684\u60a3\u8005\u75c5\u60c5\u5f97\u4ee5\u63a7\u5236\uff0c\u63a5\u53d7\u624b\u672f\u7684\u60a3\u8005\u7684\u65e0\u75be\u75c5\u751f\u5b58\u671f\u4e2d\u4f4d\u503c\u4e3a10.3\u4e2a\u6708\u3002\u6240\u6709\u63a5\u53d7\u65b0\u8f85\u52a9\u6cbb\u7597\u768419\u540d\u53d7\u8bd5\u8005\u7684PFS\u4e0eOS\u4e2d\u4f4d\u503c\u5206\u522b\u4e3a11.2\u4e2a\u6708\u4e0e51.6\u4e2a\u6708\u3002\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u4e3a36.8%\uff087\/19\uff09\uff0c\u4ee5\u76ae\u75b9\uff0826.3%\uff09\u6700\u4e3a\u5e38\u89c1\u30023\/4\u7ea7\u4e0d\u826f\u53cd\u5e94\u7684\u53d1\u751f\u7387\u4e3a15.8%\u3002<\/span><\/p>\n<\/li>\n

        • \n

          \u4e3b\u8981\u7ed3\u8bba\uff1a\u5384\u6d1b\u66ff\u5c3c\u65b0\u8f85\u52a9\u6cbb\u7597\u5728\u8fd9\u4e00\u4eba\u7fa4\u4e2d\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u7279\u5f81\uff0c\u5e76\u53ef\u63d0\u9ad8\u5176\u80bf\u7624\u7684\u5b8c\u5168\u5207\u9664\u7387\u3002<\/span><\/p>\n<\/li>\n<\/ul>\n

          <\/span>5\uff0cYue D. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018 Aug 24. pii: S2213-2600(18)30277-7. doi: 10.1016\/S2213-2600(18)30277-7. [Epub ahead of print]<\/span><\/p>\n

            \n
          • \n

            \u8bd5\u9a8c\u76ee\u7684\uff1a\u6bd4\u8f83\u5384\u6d1b\u66ff\u5c3c\u8f85\u52a9\u6cbb\u7597\u4e0e\u5316\u7597\u6539\u5584EGFR\u7a81\u53d8\u9633\u6027\u2162A\u7ea7NSCLC\u60a3\u80052\u5e74\u65e0\u75be\u75c5\u751f\u5b58\u7387\u7684\u6548\u679c\u3002<\/span><\/p>\n<\/li>\n

          • \n

            \u4e3b\u529e\u65b9\uff1a\u4e2d\u56fd\u56fd\u5bb6\u764c\u75c7\u4e34\u5e8a\u7814\u7a76\u4e2d\u5fc3\uff0c\u7531\u7f57\u6c0f\u516c\u53f8\u8d44\u52a9\u3002<\/span><\/p>\n<\/li>\n

          • \n

            \u8bd5\u9a8c\u5206\u671f\uff1a\u2161\u671f<\/span><\/p>\n<\/li>\n

          • \n

            \u53d7\u8bd5\u8005\u57fa\u672c\u7279\u5f81\uff1a\u7ec4\u7ec7\u5b66\u6216\u75c5\u7406\u5b66\u786e\u8bca\u7684\u2162A\u7ea7EGFR\u7a81\u53d8\u9633\u6027NSCLC\u5b8c\u5168\u5207\u9664\u4e14\u5148\u524d\u672a\u63a5\u53d7\u8fc7\u6297\u764c\u6cbb\u7597\u7684\u60a3\u8005\u3002<\/span><\/p>\n<\/li>\n

          • \n

            \u5165\u7ec4\u53d7\u8bd5\u8005\u4eba\u6570:102\u4eba\u3002<\/span><\/p>\n<\/li>\n

          • \n

            \u5e72\u9884\u65b9\u6cd5\uff1a\u53d7\u8bd5\u8005\u63091:1\u7684\u6bd4\u4f8b\u968f\u673a\u5206\u5165\u5384\u6d1b\u66ff\u5c3c\uff08150mg\/d\uff09\u4e0e\u5316\u7597\u7ec4\u3002\u5316\u7597\u7ec4\u7ed9\u4e884\u5468\u671f\u7684\u957f\u6625\u745e\u6ee8\u8054\u5408\u987a\u94c2\u5316\u7597\uff0c\u574721\u59291\u5468\u671f\uff0c\u5176\u4e2d\u957f\u6625\u745e\u6ee8\u5728\u6bcf\u5468\u671f\u7684\u7b2c1\u30018\u5929\u4ee525mg\/m2<\/sup>\u7684\u5242\u91cf\u9759\u8109\u6ce8\u5c04\uff0c\u800c\u987a\u94c2\u5219\u5728\u6bcf\u5468\u671f\u7684\u7b2c1\u5929\u4ee575mg\/m2<\/sup>\u7684\u5242\u91cf\u9759\u8109\u6ce8\u5c04\u3002\u4e3b\u8981\u7ed3\u5c40\u6307\u6807\u662f2\u5e74\u65e0\u75be\u75c5\u751f\u5b58\u7387\u3002<\/span><\/p>\n<\/li>\n

          • \n

            \u4e3b\u8981\u7ed3\u679c\uff1a\u968f\u8bbf\u65f6\u95f4\u4e2d\u4f4d\u503c\u4e3a33.0\u4e2a\u6708\u3002\u5384\u6d1b\u66ff\u5c3c\u7ec4\u4e0e\u5316\u7597\u7ec4\u76842\u5e74\u65e0\u75be\u75c5\u751f\u5b58\u7387\u5206\u522b\u4e3a81.4%\uff0895% CI 69.6-93.1\uff09\u4e0e44.6% (95%CI\uff1a26.9-62.4)\uff0c\u76f8\u5bf9\u98ce\u9669\u4e3a1.823\uff0895% CI 1.194-2.784; p=0.0054\uff09\u3002\u4e24\u7ec4\u76f8\u6bd42\u5e74\u65e0\u75be\u75c5\u751f\u5b58\u7387\u7684\u5dee\u503c\u4e3a36.7\uff0895% CI 15.5-58.0; p=0.0007\uff09\u3002\u5384\u6d1b\u66ff\u5c3c\u7ec4\u4e0e\u5316\u7597\u7ec4\u5185\u4efb\u610f\u7ea7\u522b\u4e0d\u826f\u53cd\u5e94\u7684\u53d1\u751f\u7387\u5206\u522b\u4e3a28%\uff08529\/50\uff09\u4e0e65%\uff0828\/43\uff09\uff0c\u5176\u4e2d\u7ea7\u522b\u22653\u7ec4\u7684\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u5206\u522b\u4e3a12%\uff086\/50\uff09\u4e0e26%\uff0811\/43\uff09\u3002\u5384\u6d1b\u66ff\u5c3c\u7ec4\u6700\u5e38\u89c1\u7684\u4e0d\u826f\u53cd\u5e94\u662f\u76ae\u75b9\uff084%\uff09\uff0c\u5316\u7597\u7ec4\u6700\u5e38\u89c1\u7684\u4e0d\u826f\u53cd\u5e94\u662f\u4e2d\u6027\u7c92\u7ec6\u80de\u8ba1\u6570\u51cf\u5c11\uff0816%\uff09\u4e0e\u9aa8\u9ad3\u6291\u5236\uff089%\uff09\u3002\u65e0\u53d7\u8bd5\u8005\u56e0\u6cbb\u7597\u800c\u6b7b\u4ea1\u3002<\/span><\/p>\n<\/li>\n

          • \n

            \u4e3b\u8981\u7ed3\u8bba\uff1a\u5305\u62ec\u5384\u6d1b\u66ff\u5c3c\u5728\u5185\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u7c7b\u836f\u7269\u53ef\u80fd\u4f1a\u5728EGFR-\u7a81\u53d8\u9633\u6027\u7684\u2162A\u7ec4NSCLC\u60a3\u8005\u7684\u8f85\u52a9\u6cbb\u7597\u4e2d\u53d1\u6325\u7740\u91cd\u8981\u7684\u4f5c\u7528\u3002<\/span><\/p>\n<\/li>\n<\/ul>\n

            \n
            \n

            2<\/span>\u4e2d\u56fdBE\u4e34\u5e8a\u8bd5\u9a8c\u5907\u6848\u4fe1\u606f<\/strong><\/p>\n<\/section>\n<\/section>\n

            \u7531\u4e8e\u5384\u6d1b\u66ff\u5c3c\u5728\u4e2d\u56fd\u7684\u5316\u5408\u7269\u4e13\u5229CN96102992.7\u5df2\u4e8e2016\u5e743\u6708\u5c4a\u6ee1\uff0c\u800c\u5176\u76d0\u9178\u76d0\u6676\u578b\u4e13\u5229CN00817848.8\u4e5f\u5c06\u4e8e2020\u5e7411\u6708\u5230\u671f\uff0c\u56e0\u6b64\u56fd\u5185\u591a\u5bb6\u4f01\u4e1a\u65e9\u5df2\u5e03\u5c40\u5384\u6d1b\u66ff\u5c3c\u4eff\u5236\u836f\u7684\u5f00\u53d1\u3002\u76ee\u524d\u5df2\u7ecf\u516c\u793a\u7684BE\u4e34\u5e8a\u8bd5\u9a8c\u4fe1\u606f\u5982\u88681\u6240\u793a\u3002<\/span><\/p>\n

            \"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\"<\/p>\n

            \n
            \n

            3<\/span>\u5384\u6d1b\u66ff\u5c3c\u5e02\u573a\u52a8\u6001<\/strong><\/p>\n<\/section>\n<\/section>\n

            1\uff0c\u5168\u7403\u5e02\u573a<\/span><\/strong><\/p>\n

            \u6839\u636e\u4e2d\u56fd\u533b\u836f\u5de5\u4e1a\u4fe1\u606f\u4e2d\u5fc3PDB\u836f\u7269\u7efc\u5408\u6570\u636e\u5e93\u4fe1\u606f\uff0c\u5384\u6d1b\u66ff\u5c3c\u7684\u5386\u5e74\u9500\u552e\u989d\u6570\u636e\u5982\u4e0b\u56fe\u6240\u793a\u3002<\/span><\/p>\n

            \"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\"<\/p>\n

            \u56fe1 \u5168\u7403\u5384\u6d1b\u66ff\u5c3c\u9500\u552e\u989d\u53d8\u5316\u60c5\u51b5<\/span>
            <\/p>\n

            \u4ece\u56fe1\u53ef\u4ee5\u770b\u51fa\uff0c\u81ea2014\u5e74\u8d77\uff0c\u5384\u6d1b\u66ff\u5c3c\u7684\u5168\u7403\u9500\u552e\u989d\u5373\u5f00\u59cb\u6301\u7eed\u4e0b\u6ed1\u3002\u6839\u636e\u7f57\u6c0f\u516c\u53f8\u76842014\u5e74\u5e74\u62a5\uff0c\u5f53\u5e74\u5384\u6d1b\u66ff\u5c3c\u5168\u7403\u9500\u552e\u989d\u7684\u4e0b\u6ed1\u4e3b\u8981\u662f\u7531\u4e8e\u6b27\u6d32\u4e0e\u5176\u4ed6\u5e02\u573a\u7684\u4e0b\u6ed1\u6240\u81f4\uff0c\u800c\u7f8e\u56fd\u5e02\u573a\u4ecd\u7136\u4fdd\u6301\u7740\u4e00\u5b9a\u7684\u589e\u957f\u52bf\u5934\u3002<\/span><\/p>\n

            \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cFDA\u867d\u7136\u66fe\u7ecf\u6279\u51c6\u8fc7Mylan\u4e0eTeva\u7684\u4eff\u5236\u5384\u6d1b\u66ff\u5c3c\uff0c\u4f46\u76ee\u524d\u8fd9\u4e24\u5bb6\u516c\u53f8\u7684\u4ea7\u54c1\u5e02\u573a\u72b6\u6001\u5747\u4e3a\u64a4\u5e02\u3002\u800c\u5728\u52a0\u62ff\u5927\uff0c\u5df2\u6709\u591a\u4e2a\u4eff\u5236\u836f\u4e0a\u5e02\u3002<\/span><\/p>\n

            2\uff0c\u56fd\u5185\u5e02\u573a<\/span><\/strong><\/p>\n

            \u6839\u636e\u4e2d\u56fd\u533b\u836f\u5de5\u4e1a\u4fe1\u606f\u4e2d\u5fc3PDB\u836f\u7269\u7efc\u5408\u6570\u636e\u5e93\uff0c\u5384\u6d1b\u66ff\u5c3c\u4ee5\u53ca\u53e6\u4e24\u79cd\u7528\u4e8e\u80ba\u764c\u9776\u5411\u6cbb\u7597\u7684\u5409\u975e\u66ff\u5c3c\u4e0e\u57c3\u514b\u66ff\u5c3c\u5728\u5168\u56fd\u6837\u672c\u533b\u9662\u5185\u7528\u836f\u91d1\u989d\u7684\u53d8\u5316\u60c5\u51b5\u5982\u56fe2\u6240\u793a\u3002<\/span><\/p>\n

            \"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\"<\/p>\n

            \u56fe2 \u6837\u672c\u533b\u9662\u5185\u80ba\u764c\u9776\u5411\u836f\u7269\u7528\u836f\u91d1\u989d<\/span>
            <\/p>\n

            \u867d\u7136\u76ee\u524d\u5384\u6d1b\u66ff\u5c3c\u5c1a\u672a\u5b9e\u73b0\u56fd\u4ea7\u5316\uff0c\u4f46\u5176\u5728\u6837\u672c\u533b\u9662\u5185\u7684\u7528\u836f\u91d1\u989d\u5374\u4e5f\u662f\u9010\u5e74\u4e0b\u6ed1\uff0c\u5df2\u88ab\u540c\u65f6\u671f\u4e0a\u5e02\u7684\u5409\u975e\u66ff\u5c3c\u4e0e\u56fd\u5185\u4f01\u4e1a\u81ea\u4e3b\u7814\u53d1\u7684\u57c3\u514b\u66ff\u5c3c\u6240\u8d76\u8d85\u3002\u7a76\u5176\u539f\u56e0\uff0c\u53ef\u80fd\u662f\u7531\u4e8e\u8d8a\u6765\u8d8a\u591a\u7684\u7814\u7a76\u8868\u660e\uff0c\u5409\u975e\u66ff\u5c3c\u5bf9\u4e9a\u6d32\u80ba\u764c\u60a3\u8005\u7684\u6548\u679c\u4f18\u4e8e\u5384\u6d1b\u66ff\u5c3c\u3002\u6bd4\u5982\uff0c\u6211\u56fd\u5357\u660c\u5927\u5b66\u7814\u7a76\u4eba\u5458\u53d1\u8868\u7684\u4e00\u9879\u7eb3\u516531\u9879\u4e34\u5e8a\u8bd5\u9a8c\u7684\u835f\u8403\u5206\u6790\u7ed3\u679c\u663e\u793a\uff0c\u5384\u6d1b\u66ff\u5c3c\u4e0e\u5409\u975e\u66ff\u5c3c\u6cbb\u7597\u665a\u671fNSCLC\u7684\u6709\u6548\u6027\u5f7c\u6b64\u76f8\u4f3c\uff0c\u4f46\u5384\u6d1b\u66ff\u5c3c\u7684\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u5374\u663e\u8457\u9ad8\u4e8e\u5409\u975e\u66ff\u5c3c\u3002<\/span><\/p>\n

            \n
            \n

            4<\/span>\u603b\u7ed3<\/strong><\/p>\n<\/section>\n<\/section>\n

            \u5384\u6d1b\u66ff\u5c3c\u66fe\u7ecf\u4e00\u5ea6\u662f\u7f57\u6c0f\u516c\u53f8\u65d7\u4e0b\u7684\u660e\u661f\u6297\u764c\u836f\uff0c\u4e5f\u662f\u5168\u7403\u8303\u56f4\u5185\u9500\u552e\u989d\u4ec5\u6b21\u4e8e\u4f0a\u9a6c\u66ff\u5c3c\u7684\u5c0f\u5206\u5b50\u9776\u5411\u836f\u7269\u3002\u8fd1\u5e74\u6765\uff0c\u968f\u7740\u5404\u56fd\u4e13\u5229\u9646\u7eed\u5c4a\u6ee1\uff0c\u5384\u6d1b\u66ff\u5c3c\u7684\u5e02\u573a\u9010\u5e74\u840e\u7f29\uff0c\u7f57\u6c0f\u516c\u53f8\u4e5f\u9010\u6e10\u5931\u53bb\u4e86\u8fdb\u4e00\u6b65\u5f00\u53d1\u8fd9\u4e00\u836f\u7269\u7684\u52a8\u529b\u3002\u6700\u8fd1\u516c\u5e03\u7684\u4e34\u5e8a\u8bd5\u9a8c\u5747\u662f\u7531\u79d1\u7814\u673a\u6784\u6240\u4e3b\u6301\u3002\u4f46\u968f\u7740\u8054\u5408\u7528\u836f\u4e34\u5e8a\u8bd5\u9a8c\u76f8\u7ee7\u53d6\u5f97\u6210\u529f\uff0c\u4ee5\u53ca\u8054\u5408\u7528\u836f\u5728\u80bf\u7624\u6cbb\u7597\u4e2d\u7684\u5730\u4f4d\u8d8a\u6765\u8d8a\u53d7\u91cd\u89c6\uff0c\u8fd9\u53ef\u80fd\u4f1a\u6709\u52a9\u4e8e\u5ef6\u7f13\u5384\u6d1b\u66ff\u5c3c\u3002<\/span><\/p>\n

            \"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\"<\/p>\n<\/section>\n

            \"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\"<\/p>\n<\/section>\n

            \"\u90a3\u4e9b\u5e74\uff0c\u6211\u4eec\u8ffd\u8fc7\u7684\u660e\u661f\u836f\u4e4b\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\"<\/p>\n

            \n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

            \u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\u662f\u5168\u7403\u9996\u4e2a\u4f5c\u7528\u4e8e\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08EGFR\uff09\u916a\u6c28\u9178\u6fc0\u9176\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5242\uff0c\u4e5f\u662f\u9996\u4e2a\u7528\u4e8e\u80ba\u764c\u9776\u5411\u6cbb\u7597\u7684\u5c0f […]<\/p>\n","protected":false},"author":1,"featured_media":53016,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/53015"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=53015"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/53015\/revisions"}],"predecessor-version":[{"id":53023,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/53015\/revisions\/53023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/53016"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=53015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=53015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=53015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}